PTGX Protagonist Therapeutics Inc

P/E 148.77

Forward P/E 38.61

Price/Sales 35.5

Beta 1.794

Div Yield --

Market Cap --

Company Analysis

Latest News

August 26, 2026

Farallon Capital Management Discloses New $669.17M Protagonist Therapeutics Stake

In a quarterly filing with the SEC, Farallon Capital Management revealed it had established a new position in Protagonist Therapeutics (PTGX) by acquiring 6.35...